ArticleMolecules (Basel, Switzerland)2024
Molecular Periphery Design Allows Control of the New Nitrofurans Antimicrobial Selectivity.
Lyubov Vinogradova, Alexey Lukin, Kristina Komarova, Maxim Zhuravlev, Artem Fadeev, Mikhail Chudinov, Elizaveta Rogacheva, Lyudmila Kraeva, Maxim Gureev, Yuri Porozov and 2 more
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
12 authors.
Lyubov VinogradovaLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.
Alexey LukinLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.ORCID 0000-0001-6162-4851 Kristina KomarovaLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.
Maxim ZhuravlevLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.
Artem FadeevLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.
Mikhail ChudinovLomonosov Institute of Fine Chemical Technologies, MIREA-Russian Technological University, 119454 Moscow, Russia.ORCID 0000-0001-9735-9690 Elizaveta RogachevaPasteur Institute of Epidemiology and Microbiology, 197101 Saint Petersburg, Russia.
Lyudmila KraevaPasteur Institute of Epidemiology and Microbiology, 197101 Saint Petersburg, Russia.
Maxim GureevInstitute of Cytology, Russian Academy of Sciences, Tikhoretsky Ave. 4, 194064 Saint Petersburg, Russia.ORCID 0000-0002-0385-922X Yuri PorozovLaboratory of Angiopathology, The Institute of General Pathology and Pathophysiology, 8 Baltiyskaya Street, 125315 Moscow, Russia.ORCID 0000-0002-5450-3135 Marine DogonadzeSaint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint Petersburg, Russia.
Tatiana VinogradovaSaint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation, 191036 Saint Petersburg, Russia.
Funding
Ministry of Science and Higher Education of the Russian Federation 075-15-2021-689
6 · The paper itselfAbstract
A series of 13 new 3-substituted 5-(5-nitro-2-furyl)-1,2,4-oxadiazoles was synthesized from different aminonitriles. All compounds were screened in the disc diffusion test at a 100 μg/mL concentration to determine the bacterial growth inhibition zone presence and diameter, and then the minimum inhibitory concentrations (MICs) were determined for the most active compounds by serial dilution. The compounds showed antibacterial activity against ESKAPE bacteria, predominantly suppressing the growth of 5 species out of the panel. Some compounds had similar or lower MICs against ESKAPE pathogens compared to ciprofloxacin, nitrofurantoin, and furazidin. In particular, 3-azetidin-3-yl-5-(5-nitro-2-furyl)-1,2,4-oxadiazole (
Indexed as
Anti-Bacterial AgentsMicrobial Sensitivity TestsMolecular Docking SimulationNitrofuransDrug DesignMolecular StructureOxadiazolesStaphylococcus aureusStructure-Activity RelationshipAnti-Bacterial AgentsNitrofuransOxadiazolesantibacterial selectivityazoreductaseESKAPEflexible dockingM. tuberculosisnitrofuransnitroreductasestrained ligand–protein interactions
Identifiers
PMID39064943
PMCPMC11279955
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390